First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II randomized study
一线治疗局部晚期或转移性胰腺导管腺癌：化疗、舒鲁法替尼（一种血管紧张素免疫激酶抑制剂）和卡瑞利珠单抗（一种抗PD-1抗体）联合治疗：一项Ib/II期随机研究
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02441-2
Jia, Ru; Si, Hai-Yan; Fan, Meng-Jiao; Zhang, Nan; Deng, Guo-Chao; Liu, Fang-Fang; Han, Lu; Gou, Miao-Miao; Tan, Zhao-Li; Zhang, Xia; Wang, Yan-Rong; Shi, Yue; Zhang, Yao-Yue; Jia, Yu-Shan; Wang, Yu-Qi; Han, Quan-Li; Wang, Zhi-Kuan; Dai, Guang-Hai
